table of content
1 Introduction to Research & Analysis Reports
1.1 Neurodegenerative Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurodegenerative Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurodegenerative Drugs Overall Market Size
2.1 Global Neurodegenerative Drugs Market Size: 2023 VS 2030
2.2 Global Neurodegenerative Drugs Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Neurodegenerative Drugs Sales: 2019-2030
3 Company Landscape
3.1 Top Neurodegenerative Drugs Players in Global Market
3.2 Top Global Neurodegenerative Drugs Companies Ranked by Revenue
3.3 Global Neurodegenerative Drugs Revenue by Companies
3.4 Global Neurodegenerative Drugs Sales by Companies
3.5 Global Neurodegenerative Drugs Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Neurodegenerative Drugs Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Neurodegenerative Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neurodegenerative Drugs Players in Global Market
3.8.1 List of Global Tier 1 Neurodegenerative Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Neurodegenerative Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neurodegenerative Drugs Market Size Markets, 2023 & 2030
4.1.2 NMDA
4.1.3 SSRIs
4.1.4 Dopamine Inhibitors
4.2 By Type - Global Neurodegenerative Drugs Revenue & Forecasts
4.2.1 By Type - Global Neurodegenerative Drugs Revenue, 2019-2024
4.2.2 By Type - Global Neurodegenerative Drugs Revenue, 2025-2030
4.2.3 By Type - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
4.3 By Type - Global Neurodegenerative Drugs Sales & Forecasts
4.3.1 By Type - Global Neurodegenerative Drugs Sales, 2019-2024
4.3.2 By Type - Global Neurodegenerative Drugs Sales, 2025-2030
4.3.3 By Type - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
4.4 By Type - Global Neurodegenerative Drugs Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neurodegenerative Drugs Market Size, 2023 & 2030
5.1.2 Parkinson?s Disease
5.1.3 Huntington Disease
5.1.4 Amyotrophic Lateral Sclerosis
5.1.5 Alzheimer?s Disease
5.2 By Application - Global Neurodegenerative Drugs Revenue & Forecasts
5.2.1 By Application - Global Neurodegenerative Drugs Revenue, 2019-2024
5.2.2 By Application - Global Neurodegenerative Drugs Revenue, 2025-2030
5.2.3 By Application - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
5.3 By Application - Global Neurodegenerative Drugs Sales & Forecasts
5.3.1 By Application - Global Neurodegenerative Drugs Sales, 2019-2024
5.3.2 By Application - Global Neurodegenerative Drugs Sales, 2025-2030
5.3.3 By Application - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
5.4 By Application - Global Neurodegenerative Drugs Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Neurodegenerative Drugs Market Size, 2023 & 2030
6.2 By Region - Global Neurodegenerative Drugs Revenue & Forecasts
6.2.1 By Region - Global Neurodegenerative Drugs Revenue, 2019-2024
6.2.2 By Region - Global Neurodegenerative Drugs Revenue, 2025-2030
6.2.3 By Region - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
6.3 By Region - Global Neurodegenerative Drugs Sales & Forecasts
6.3.1 By Region - Global Neurodegenerative Drugs Sales, 2019-2024
6.3.2 By Region - Global Neurodegenerative Drugs Sales, 2025-2030
6.3.3 By Region - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Neurodegenerative Drugs Revenue, 2019-2030
6.4.2 By Country - North America Neurodegenerative Drugs Sales, 2019-2030
6.4.3 US Neurodegenerative Drugs Market Size, 2019-2030
6.4.4 Canada Neurodegenerative Drugs Market Size, 2019-2030
6.4.5 Mexico Neurodegenerative Drugs Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Neurodegenerative Drugs Revenue, 2019-2030
6.5.2 By Country - Europe Neurodegenerative Drugs Sales, 2019-2030
6.5.3 Germany Neurodegenerative Drugs Market Size, 2019-2030
6.5.4 France Neurodegenerative Drugs Market Size, 2019-2030
6.5.5 U.K. Neurodegenerative Drugs Market Size, 2019-2030
6.5.6 Italy Neurodegenerative Drugs Market Size, 2019-2030
6.5.7 Russia Neurodegenerative Drugs Market Size, 2019-2030
6.5.8 Nordic Countries Neurodegenerative Drugs Market Size, 2019-2030
6.5.9 Benelux Neurodegenerative Drugs Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Neurodegenerative Drugs Revenue, 2019-2030
6.6.2 By Region - Asia Neurodegenerative Drugs Sales, 2019-2030
6.6.3 China Neurodegenerative Drugs Market Size, 2019-2030
6.6.4 Japan Neurodegenerative Drugs Market Size, 2019-2030
6.6.5 South Korea Neurodegenerative Drugs Market Size, 2019-2030
6.6.6 Southeast Asia Neurodegenerative Drugs Market Size, 2019-2030
6.6.7 India Neurodegenerative Drugs Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Neurodegenerative Drugs Revenue, 2019-2030
6.7.2 By Country - South America Neurodegenerative Drugs Sales, 2019-2030
6.7.3 Brazil Neurodegenerative Drugs Market Size, 2019-2030
6.7.4 Argentina Neurodegenerative Drugs Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neurodegenerative Drugs Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Neurodegenerative Drugs Sales, 2019-2030
6.8.3 Turkey Neurodegenerative Drugs Market Size, 2019-2030
6.8.4 Israel Neurodegenerative Drugs Market Size, 2019-2030
6.8.5 Saudi Arabia Neurodegenerative Drugs Market Size, 2019-2030
6.8.6 UAE Neurodegenerative Drugs Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Neurodegenerative Drugs Major Product Offerings
7.1.4 Novartis Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.1.5 Novartis Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Neurodegenerative Drugs Major Product Offerings
7.2.4 Pfizer Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.2.5 Pfizer Key News & Latest Developments
7.3 Merck Serono
7.3.1 Merck Serono Company Summary
7.3.2 Merck Serono Business Overview
7.3.3 Merck Serono Neurodegenerative Drugs Major Product Offerings
7.3.4 Merck Serono Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.3.5 Merck Serono Key News & Latest Developments
7.4 Biogen Idec
7.4.1 Biogen Idec Company Summary
7.4.2 Biogen Idec Business Overview
7.4.3 Biogen Idec Neurodegenerative Drugs Major Product Offerings
7.4.4 Biogen Idec Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.4.5 Biogen Idec Key News & Latest Developments
7.5 TEVA
7.5.1 TEVA Company Summary
7.5.2 TEVA Business Overview
7.5.3 TEVA Neurodegenerative Drugs Major Product Offerings
7.5.4 TEVA Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.5.5 TEVA Key News & Latest Developments
7.6 UCB
7.6.1 UCB Company Summary
7.6.2 UCB Business Overview
7.6.3 UCB Neurodegenerative Drugs Major Product Offerings
7.6.4 UCB Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.6.5 UCB Key News & Latest Developments
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Company Summary
7.7.2 Boehringer Ingelheim Business Overview
7.7.3 Boehringer Ingelheim Neurodegenerative Drugs Major Product Offerings
7.7.4 Boehringer Ingelheim Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.7.5 Boehringer Ingelheim Key News & Latest Developments
7.8 Sanofi
7.8.1 Sanofi Company Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Neurodegenerative Drugs Major Product Offerings
7.8.4 Sanofi Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.8.5 Sanofi Key News & Latest Developments
7.9 GlaxoSmithKline
7.9.1 GlaxoSmithKline Company Summary
7.9.2 GlaxoSmithKline Business Overview
7.9.3 GlaxoSmithKline Neurodegenerative Drugs Major Product Offerings
7.9.4 GlaxoSmithKline Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.9.5 GlaxoSmithKline Key News & Latest Developments
7.10 Livzon Pharmaceutical
7.10.1 Livzon Pharmaceutical Company Summary
7.10.2 Livzon Pharmaceutical Business Overview
7.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.10.5 Livzon Pharmaceutical Key News & Latest Developments
7.11 Haisco Pharmaceutical
7.11.1 Haisco Pharmaceutical Company Summary
7.11.2 Haisco Pharmaceutical Business Overview
7.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.11.5 Haisco Pharmaceutical Key News & Latest Developments
7.12 Jingxin Pharmaceutical
7.12.1 Jingxin Pharmaceutical Company Summary
7.12.2 Jingxin Pharmaceutical Business Overview
7.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.12.5 Jingxin Pharmaceutical Key News & Latest Developments
7.13 Dongcheng Biochemicals
7.13.1 Dongcheng Biochemicals Company Summary
7.13.2 Dongcheng Biochemicals Business Overview
7.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Major Product Offerings
7.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.13.5 Dongcheng Biochemicals Key News & Latest Developments
7.14 Hisun Pharmaceutical
7.14.1 Hisun Pharmaceutical Company Summary
7.14.2 Hisun Pharmaceutical Business Overview
7.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.14.5 Hisun Pharmaceutical Key News & Latest Developments
7.15 Luye Pharma
7.15.1 Luye Pharma Company Summary
7.15.2 Luye Pharma Business Overview
7.15.3 Luye Pharma Neurodegenerative Drugs Major Product Offerings
7.15.4 Luye Pharma Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.15.5 Luye Pharma Key News & Latest Developments
7.16 Ark Pharmaceutical
7.16.1 Ark Pharmaceutical Company Summary
7.16.2 Ark Pharmaceutical Business Overview
7.16.3 Ark Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.16.4 Ark Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.16.5 Ark Pharmaceutical Key News & Latest Developments
7.17 Kanghong Pharmaceutical
7.17.1 Kanghong Pharmaceutical Company Summary
7.17.2 Kanghong Pharmaceutical Business Overview
7.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.17.5 Kanghong Pharmaceutical Key News & Latest Developments
7.18 Huahai Pharmaceutical
7.18.1 Huahai Pharmaceutical Company Summary
7.18.2 Huahai Pharmaceutical Business Overview
7.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.18.5 Huahai Pharmaceutical Key News & Latest Developments
7.19 BORA PHARMACEUTICALS
7.19.1 BORA PHARMACEUTICALS Company Summary
7.19.2 BORA PHARMACEUTICALS Business Overview
7.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Major Product Offerings
7.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.19.5 BORA PHARMACEUTICALS Key News & Latest Developments
8 Global Neurodegenerative Drugs Production Capacity, Analysis
8.1 Global Neurodegenerative Drugs Production Capacity, 2019-2030
8.2 Neurodegenerative Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Neurodegenerative Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neurodegenerative Drugs Supply Chain Analysis
10.1 Neurodegenerative Drugs Industry Value Chain
10.2 Neurodegenerative Drugs Upstream Market
10.3 Neurodegenerative Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neurodegenerative Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
